中枢神経系医薬品市場：薬効分類、疾患、薬物タイプ、流通チャネル別-2023-2030年の世界予測

中枢神経系医薬品の世界市場は、2023年に207億1,000万米ドル、CAGR 9.60%で大幅な成長が予測され、2030年には399億9,000万米ドルという驚異的な規模に達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の中枢神経系医薬品市場を評価するために不可欠です。ビジネス戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.中枢神経系医薬品の世界市場規模および予測は？

2.予測期間中、世界の中枢神経系医薬品市場を形成するCOVID-19の阻害要因と影響は？

3.中枢神経系医薬品の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.中枢神経系医薬品の世界市場における競争戦略は？

5.中枢神経系医薬品の世界市場における技術動向と規制の枠組みは？

6.中枢神経系医薬品の世界市場における主要ベンダーの市場シェアは？

7.中枢神経系医薬品の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で神経障害および認知障害の発生率が増加
    • 神経学的危険因子と症状に関する知識を広めるための政府プログラムと啓発活動の強化
    • 神経合併症を伴う高齢者人口の増加
  • 抑制要因
    • 創薬と開発には多額の資本投資と適切なインフラストラクチャが必要
  • 機会
    • 精神医学および神経学分野の独特で変化する需要を満たすための継続的な医薬品の進化
    • CNS創薬における人工知能と機械学習の導入
  • 課題
    • 製品承認に関する厳しい規制と製品リコールに関する懸念
    • 有能な研究が行われる中、神経学的分野における主題の専門知識が不足している
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 中枢神経系医薬品市場薬物クラス別

• 鎮痛剤
• 麻酔薬
• 抗てんかん薬
• 抗パーキンソン病薬
• 抗うつ薬

第7章 中枢神経系医薬品市場病気別

• 中枢神経系外傷
• 感染症
• メンタルヘルス
• 神経変性疾患
• 神経血管疾患

第8章 中枢神経系医薬品市場薬剤の種類別

• 生物製剤
• 非生物製剤

第9章 中枢神経系医薬品市場：流通チャネル別

• 病院薬局
• オンライン
• 小売薬局

第10章 南北アメリカの中枢神経系医薬品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の中枢神経系医薬品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの中枢神経系医薬品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別
  • 合併・買収
  • 契約、コラボレーション、パートナーシップ

第14章 掲載企業一覧

第15章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2022 VS 2030 (%)
• FIGURE 5. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2022 VS 2030 (%)
• FIGURE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2030 (%)
• FIGURE 7. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
• FIGURE 8. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 9. CENTRAL NERVOUS SYSTEM DRUGS MARKET DYNAMICS
• FIGURE 10. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 18. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 19. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 5. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 11. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS TRAUMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 17. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASSES, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 192. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 193. CENTRAL NERVOUS SYSTEM DRUGS MARKET LICENSE & PRICING

The Global Central Nervous System Drugs Market is forecasted to grow significantly, with a projected USD 20.71 billion in 2023 at a CAGR of 9.60% and expected to reach a staggering USD 39.99 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Classes, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, and Antidepressant. The Analgesics commanded largest market share of 22.49% in 2022, followed by Antidepressant.

Based on Diseases, market is studied across CNS Trauma, Infectious Diseases, Mental Health, Neurodegenerative Diseases, and Neurovascular Diseases. The Infectious Diseases commanded largest market share of 28.56% in 2022, followed by Mental Health.

Based on Drug Type, market is studied across Biologics and Non-Biologics. The Non-Biologics commanded largest market share of 71.68% in 2022, followed by Biologics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 62.58% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 41.45% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Drugs Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Central Nervous System Drugs Market, by Drug Classes, 2022 vs 2030
• 4.3. Central Nervous System Drugs Market, by Diseases, 2022 vs 2030
• 4.4. Central Nervous System Drugs Market, by Drug Type, 2022 vs 2030
• 4.5. Central Nervous System Drugs Market, by Distribution Channel, 2022 vs 2030
• 4.6. Central Nervous System Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of neurological and cognitive disorders across the globe
    • 5.1.1.2. Ascending government programs and awareness activities to spread the knowledge about neurological risk factors and symptoms
    • 5.1.1.3. Rise in geriatric population with neurological complications
  • 5.1.2. Restraints
    • 5.1.2.1. Requirement of high capital investment and adequate infrastructure for drug discovery and development
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing drug evolvement to meet the unique and changing demands of psychiatry and neurology field
    • 5.1.3.2. Adoption of artificial intelligence and machine learning in CNS drug discovery
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulations for product approvals and concern regarding product recalls
    • 5.1.4.2. Dearth of subject expertise in the neurological field amid the competent studies
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Central Nervous System Drugs Market, by Drug Classes

• 6.1. Introduction
• 6.2. Analgesics
• 6.3. Anesthetics
• 6.4. Anti-Epileptics
• 6.5. Anti-Parkinson Drugs
• 6.6. Antidepressant

7. Central Nervous System Drugs Market, by Diseases

• 7.1. Introduction
• 7.2. CNS Trauma
• 7.3. Infectious Diseases
• 7.4. Mental Health
• 7.5. Neurodegenerative Diseases
• 7.6. Neurovascular Diseases

8. Central Nervous System Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Biologics
• 8.3. Non-Biologics

9. Central Nervous System Drugs Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacies
• 9.3. Online
• 9.4. Retail Pharmacies

10. Americas Central Nervous System Drugs Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Central Nervous System Drugs Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Central Nervous System Drugs Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. FPNV Positioning Matrix
• 13.2. Market Share Analysis, By Key Player
• 13.3. Competitive Scenario Analysis, By Key Player
  • 13.3.1. Merger & Acquisition
    • 13.3.1.1. Neuraxpharm announces closing of acquisition of established products from Sanofi
    • 13.3.1.2. Intrinsic Medicine enters merger deal with Phoenix Biotech
    • 13.3.1.3. Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
    • 13.3.1.4. AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
  • 13.3.2. Agreement, Collaboration, & Partnership
    • 13.3.2.1. Astex and Cardiff University announce drug discovery collaboration
    • 13.3.2.2. PrecisionLife and Ono sign multi-target partnership for CNS disorders
    • 13.3.2.3. Collaboration will focus on therapy targets for CNS disorders
    • 13.3.2.4. Gensaic enters into collaboration to develop
    • 13.3.2.5. IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery
    • 13.3.2.6. AbbVie and Gedeon Richter Announce Collaboration in Neuropsychiatric Diseases

14. List of Company Mentioned

15. Appendix

• 15.1. Discussion Guide
• 15.2. License & Pricing